nodes	percent_of_prediction	percent_of_DWPC	metapath
Metaxalone—Gastrointestinal tract irritation—Estramustine—prostate cancer	0.0694	0.0694	CcSEcCtD
Metaxalone—Haemolytic anaemia—Flutamide—prostate cancer	0.0176	0.0176	CcSEcCtD
Metaxalone—Irritability—Estrone—prostate cancer	0.0164	0.0164	CcSEcCtD
Metaxalone—Gastrointestinal tract irritation—Capecitabine—prostate cancer	0.0153	0.0153	CcSEcCtD
Metaxalone—Abdominal discomfort—Estramustine—prostate cancer	0.0149	0.0149	CcSEcCtD
Metaxalone—Irritability—Estradiol valerate/Dienogest—prostate cancer	0.0143	0.0143	CcSEcCtD
Metaxalone—Drowsiness—Flutamide—prostate cancer	0.0122	0.0122	CcSEcCtD
Metaxalone—Jaundice—Flutamide—prostate cancer	0.0119	0.0119	CcSEcCtD
Metaxalone—Abdominal discomfort—Degarelix—prostate cancer	0.0118	0.0118	CcSEcCtD
Metaxalone—Tension—Estrone—prostate cancer	0.0102	0.0102	CcSEcCtD
Metaxalone—Nervousness—Estrone—prostate cancer	0.01	0.01	CcSEcCtD
Metaxalone—Leukopenia—Estramustine—prostate cancer	0.0097	0.0097	CcSEcCtD
Metaxalone—Tension—Nilutamide—prostate cancer	0.00943	0.00943	CcSEcCtD
Metaxalone—Tension—Flutamide—prostate cancer	0.00939	0.00939	CcSEcCtD
Metaxalone—Nervousness—Nilutamide—prostate cancer	0.00933	0.00933	CcSEcCtD
Metaxalone—Irritability—Ethinyl Estradiol—prostate cancer	0.00929	0.00929	CcSEcCtD
Metaxalone—Nervousness—Flutamide—prostate cancer	0.00929	0.00929	CcSEcCtD
Metaxalone—Tension—Estradiol valerate/Dienogest—prostate cancer	0.00886	0.00886	CcSEcCtD
Metaxalone—Nervousness—Estradiol valerate/Dienogest—prostate cancer	0.00877	0.00877	CcSEcCtD
Metaxalone—Jaundice—Bicalutamide—prostate cancer	0.00865	0.00865	CcSEcCtD
Metaxalone—Leukopenia—Nilutamide—prostate cancer	0.0086	0.0086	CcSEcCtD
Metaxalone—Leukopenia—Flutamide—prostate cancer	0.00856	0.00856	CcSEcCtD
Metaxalone—Anaphylactic shock—Estrone—prostate cancer	0.00844	0.00844	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Conjugated Estrogens—prostate cancer	0.0082	0.0082	CcSEcCtD
Metaxalone—Irritability—Conjugated Estrogens—prostate cancer	0.00758	0.00758	CcSEcCtD
Metaxalone—Anaphylactic shock—Estradiol valerate/Dienogest—prostate cancer	0.00737	0.00737	CcSEcCtD
Metaxalone—Leukopenia—Cabazitaxel—prostate cancer	0.00724	0.00724	CcSEcCtD
Metaxalone—Anaphylactic shock—Degarelix—prostate cancer	0.00701	0.00701	CcSEcCtD
Metaxalone—Somnolence—Flutamide—prostate cancer	0.00694	0.00694	CcSEcCtD
Metaxalone—Tension—Bicalutamide—prostate cancer	0.00681	0.00681	CcSEcCtD
Metaxalone—Nervousness—Bicalutamide—prostate cancer	0.00674	0.00674	CcSEcCtD
Metaxalone—Abdominal discomfort—Conjugated Estrogens—prostate cancer	0.00658	0.00658	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Estradiol—prostate cancer	0.00656	0.00656	CcSEcCtD
Metaxalone—Pruritus—Estramustine—prostate cancer	0.00625	0.00625	CcSEcCtD
Metaxalone—Drowsiness—Goserelin—prostate cancer	0.00618	0.00618	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Mitoxantrone—prostate cancer	0.00612	0.00612	CcSEcCtD
Metaxalone—Irritability—Estradiol—prostate cancer	0.00606	0.00606	CcSEcCtD
Metaxalone—Jaundice—Goserelin—prostate cancer	0.00602	0.00602	CcSEcCtD
Metaxalone—Pruritus—Estrone—prostate cancer	0.00597	0.00597	CcSEcCtD
Metaxalone—Vomiting—Estramustine—prostate cancer	0.00562	0.00562	CcSEcCtD
Metaxalone—Dizziness—Estrone—prostate cancer	0.00558	0.00558	CcSEcCtD
Metaxalone—Rash—Estramustine—prostate cancer	0.00557	0.00557	CcSEcCtD
Metaxalone—Dermatitis—Estramustine—prostate cancer	0.00557	0.00557	CcSEcCtD
Metaxalone—Pruritus—Nilutamide—prostate cancer	0.00555	0.00555	CcSEcCtD
Metaxalone—Headache—Estramustine—prostate cancer	0.00554	0.00554	CcSEcCtD
Metaxalone—Pruritus—Flutamide—prostate cancer	0.00552	0.00552	CcSEcCtD
Metaxalone—Vomiting—Abiraterone—prostate cancer	0.00546	0.00546	CcSEcCtD
Metaxalone—Hypersensitivity—Estradiol valerate/Dienogest—prostate cancer	0.00543	0.00543	CcSEcCtD
Metaxalone—Rash—Abiraterone—prostate cancer	0.00541	0.00541	CcSEcCtD
Metaxalone—Dermatitis—Abiraterone—prostate cancer	0.00541	0.00541	CcSEcCtD
Metaxalone—Vomiting—Estrone—prostate cancer	0.00537	0.00537	CcSEcCtD
Metaxalone—Rash—Estrone—prostate cancer	0.00532	0.00532	CcSEcCtD
Metaxalone—Dermatitis—Estrone—prostate cancer	0.00532	0.00532	CcSEcCtD
Metaxalone—Headache—Estrone—prostate cancer	0.00529	0.00529	CcSEcCtD
Metaxalone—Abdominal discomfort—Estradiol—prostate cancer	0.00526	0.00526	CcSEcCtD
Metaxalone—Nausea—Estramustine—prostate cancer	0.00525	0.00525	CcSEcCtD
Metaxalone—Pruritus—Estradiol valerate/Dienogest—prostate cancer	0.00521	0.00521	CcSEcCtD
Metaxalone—Dizziness—Nilutamide—prostate cancer	0.00519	0.00519	CcSEcCtD
Metaxalone—Dizziness—Flutamide—prostate cancer	0.00516	0.00516	CcSEcCtD
Metaxalone—Hypersensitivity—Degarelix—prostate cancer	0.00516	0.00516	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Etoposide—prostate cancer	0.00509	0.00509	CcSEcCtD
Metaxalone—Somnolence—Bicalutamide—prostate cancer	0.00503	0.00503	CcSEcCtD
Metaxalone—Nausea—Estrone—prostate cancer	0.00502	0.00502	CcSEcCtD
Metaxalone—Vomiting—Nilutamide—prostate cancer	0.00499	0.00499	CcSEcCtD
Metaxalone—Vomiting—Flutamide—prostate cancer	0.00497	0.00497	CcSEcCtD
Metaxalone—Pruritus—Degarelix—prostate cancer	0.00496	0.00496	CcSEcCtD
Metaxalone—Rash—Nilutamide—prostate cancer	0.00495	0.00495	CcSEcCtD
Metaxalone—Dermatitis—Nilutamide—prostate cancer	0.00494	0.00494	CcSEcCtD
Metaxalone—Rash—Flutamide—prostate cancer	0.00492	0.00492	CcSEcCtD
Metaxalone—Dermatitis—Flutamide—prostate cancer	0.00492	0.00492	CcSEcCtD
Metaxalone—Headache—Nilutamide—prostate cancer	0.00491	0.00491	CcSEcCtD
Metaxalone—Headache—Flutamide—prostate cancer	0.00489	0.00489	CcSEcCtD
Metaxalone—Dizziness—Estradiol valerate/Dienogest—prostate cancer	0.00487	0.00487	CcSEcCtD
Metaxalone—Hypersensitivity—Cabazitaxel—prostate cancer	0.00486	0.00486	CcSEcCtD
Metaxalone—Jaundice—Estradiol—prostate cancer	0.00477	0.00477	CcSEcCtD
Metaxalone—Tension—Goserelin—prostate cancer	0.00474	0.00474	CcSEcCtD
Metaxalone—Tension—Conjugated Estrogens—prostate cancer	0.00469	0.00469	CcSEcCtD
Metaxalone—Nervousness—Goserelin—prostate cancer	0.00469	0.00469	CcSEcCtD
Metaxalone—Vomiting—Estradiol valerate/Dienogest—prostate cancer	0.00469	0.00469	CcSEcCtD
Metaxalone—Nausea—Nilutamide—prostate cancer	0.00466	0.00466	CcSEcCtD
Metaxalone—Rash—Estradiol valerate/Dienogest—prostate cancer	0.00465	0.00465	CcSEcCtD
Metaxalone—Nervousness—Conjugated Estrogens—prostate cancer	0.00464	0.00464	CcSEcCtD
Metaxalone—Dermatitis—Estradiol valerate/Dienogest—prostate cancer	0.00464	0.00464	CcSEcCtD
Metaxalone—Nausea—Flutamide—prostate cancer	0.00464	0.00464	CcSEcCtD
Metaxalone—Dizziness—Degarelix—prostate cancer	0.00463	0.00463	CcSEcCtD
Metaxalone—Headache—Estradiol valerate/Dienogest—prostate cancer	0.00462	0.00462	CcSEcCtD
Metaxalone—Drowsiness—Mitoxantrone—prostate cancer	0.00456	0.00456	CcSEcCtD
Metaxalone—Vomiting—Degarelix—prostate cancer	0.00446	0.00446	CcSEcCtD
Metaxalone—Jaundice—Mitoxantrone—prostate cancer	0.00445	0.00445	CcSEcCtD
Metaxalone—Rash—Degarelix—prostate cancer	0.00442	0.00442	CcSEcCtD
Metaxalone—Dermatitis—Degarelix—prostate cancer	0.00441	0.00441	CcSEcCtD
Metaxalone—Headache—Degarelix—prostate cancer	0.00439	0.00439	CcSEcCtD
Metaxalone—Haemolytic anaemia—Capecitabine—prostate cancer	0.00439	0.00439	CcSEcCtD
Metaxalone—Nausea—Estradiol valerate/Dienogest—prostate cancer	0.00438	0.00438	CcSEcCtD
Metaxalone—Dizziness—Cabazitaxel—prostate cancer	0.00436	0.00436	CcSEcCtD
Metaxalone—Leukopenia—Goserelin—prostate cancer	0.00432	0.00432	CcSEcCtD
Metaxalone—Vomiting—Cabazitaxel—prostate cancer	0.0042	0.0042	CcSEcCtD
Metaxalone—Hypersensitivity—Bicalutamide—prostate cancer	0.00417	0.00417	CcSEcCtD
Metaxalone—Nausea—Degarelix—prostate cancer	0.00416	0.00416	CcSEcCtD
Metaxalone—Headache—Cabazitaxel—prostate cancer	0.00414	0.00414	CcSEcCtD
Metaxalone—Pruritus—Bicalutamide—prostate cancer	0.00401	0.00401	CcSEcCtD
Metaxalone—Anaphylactic shock—Goserelin—prostate cancer	0.00394	0.00394	CcSEcCtD
Metaxalone—Nausea—Cabazitaxel—prostate cancer	0.00392	0.00392	CcSEcCtD
Metaxalone—Anaphylactic shock—Conjugated Estrogens—prostate cancer	0.0039	0.0039	CcSEcCtD
Metaxalone—Irritability—Capecitabine—prostate cancer	0.00378	0.00378	CcSEcCtD
Metaxalone—Tension—Estradiol—prostate cancer	0.00375	0.00375	CcSEcCtD
Metaxalone—Dizziness—Bicalutamide—prostate cancer	0.00374	0.00374	CcSEcCtD
Metaxalone—Nervousness—Estradiol—prostate cancer	0.00372	0.00372	CcSEcCtD
Metaxalone—Jaundice—Etoposide—prostate cancer	0.0037	0.0037	CcSEcCtD
Metaxalone—Vomiting—Bicalutamide—prostate cancer	0.0036	0.0036	CcSEcCtD
Metaxalone—Rash—Bicalutamide—prostate cancer	0.00357	0.00357	CcSEcCtD
Metaxalone—Dermatitis—Bicalutamide—prostate cancer	0.00357	0.00357	CcSEcCtD
Metaxalone—Headache—Bicalutamide—prostate cancer	0.00355	0.00355	CcSEcCtD
Metaxalone—Hypersensitivity—Ethinyl Estradiol—prostate cancer	0.00353	0.00353	CcSEcCtD
Metaxalone—Somnolence—Goserelin—prostate cancer	0.0035	0.0035	CcSEcCtD
Metaxalone—Somnolence—Conjugated Estrogens—prostate cancer	0.00347	0.00347	CcSEcCtD
Metaxalone—Pruritus—Ethinyl Estradiol—prostate cancer	0.00339	0.00339	CcSEcCtD
Metaxalone—Irritability—Prednisone—prostate cancer	0.00337	0.00337	CcSEcCtD
Metaxalone—Nausea—Bicalutamide—prostate cancer	0.00336	0.00336	CcSEcCtD
Metaxalone—Abdominal discomfort—Capecitabine—prostate cancer	0.00328	0.00328	CcSEcCtD
Metaxalone—Leukopenia—Mitoxantrone—prostate cancer	0.00319	0.00319	CcSEcCtD
Metaxalone—Dizziness—Ethinyl Estradiol—prostate cancer	0.00317	0.00317	CcSEcCtD
Metaxalone—Anaphylactic shock—Estradiol—prostate cancer	0.00312	0.00312	CcSEcCtD
Metaxalone—Jaundice—Docetaxel—prostate cancer	0.00307	0.00307	CcSEcCtD
Metaxalone—Vomiting—Ethinyl Estradiol—prostate cancer	0.00304	0.00304	CcSEcCtD
Metaxalone—Rash—Ethinyl Estradiol—prostate cancer	0.00302	0.00302	CcSEcCtD
Metaxalone—Dermatitis—Ethinyl Estradiol—prostate cancer	0.00302	0.00302	CcSEcCtD
Metaxalone—Headache—Ethinyl Estradiol—prostate cancer	0.003	0.003	CcSEcCtD
Metaxalone—Jaundice—Capecitabine—prostate cancer	0.00298	0.00298	CcSEcCtD
Metaxalone—Anaphylactic shock—Mitoxantrone—prostate cancer	0.00291	0.00291	CcSEcCtD
Metaxalone—Hypersensitivity—Goserelin—prostate cancer	0.0029	0.0029	CcSEcCtD
Metaxalone—Hypersensitivity—Conjugated Estrogens—prostate cancer	0.00287	0.00287	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Epirubicin—prostate cancer	0.00285	0.00285	CcSEcCtD
Metaxalone—Nausea—Ethinyl Estradiol—prostate cancer	0.00284	0.00284	CcSEcCtD
Metaxalone—Pruritus—Goserelin—prostate cancer	0.00279	0.00279	CcSEcCtD
Metaxalone—Somnolence—Estradiol—prostate cancer	0.00278	0.00278	CcSEcCtD
Metaxalone—Pruritus—Conjugated Estrogens—prostate cancer	0.00276	0.00276	CcSEcCtD
Metaxalone—Leukopenia—Etoposide—prostate cancer	0.00265	0.00265	CcSEcCtD
Metaxalone—Anaphylactoid reaction—Doxorubicin—prostate cancer	0.00264	0.00264	CcSEcCtD
Metaxalone—Dizziness—Goserelin—prostate cancer	0.0026	0.0026	CcSEcCtD
Metaxalone—Somnolence—Mitoxantrone—prostate cancer	0.00259	0.00259	CcSEcCtD
Metaxalone—Dizziness—Conjugated Estrogens—prostate cancer	0.00258	0.00258	CcSEcCtD
Metaxalone—Vomiting—Goserelin—prostate cancer	0.0025	0.0025	CcSEcCtD
Metaxalone—Rash—Goserelin—prostate cancer	0.00248	0.00248	CcSEcCtD
Metaxalone—Dermatitis—Goserelin—prostate cancer	0.00248	0.00248	CcSEcCtD
Metaxalone—Vomiting—Conjugated Estrogens—prostate cancer	0.00248	0.00248	CcSEcCtD
Metaxalone—Headache—Goserelin—prostate cancer	0.00247	0.00247	CcSEcCtD
Metaxalone—Rash—Conjugated Estrogens—prostate cancer	0.00246	0.00246	CcSEcCtD
Metaxalone—Dermatitis—Conjugated Estrogens—prostate cancer	0.00246	0.00246	CcSEcCtD
Metaxalone—Headache—Conjugated Estrogens—prostate cancer	0.00244	0.00244	CcSEcCtD
Metaxalone—Anaphylactic shock—Etoposide—prostate cancer	0.00242	0.00242	CcSEcCtD
Metaxalone—Nausea—Goserelin—prostate cancer	0.00234	0.00234	CcSEcCtD
Metaxalone—Nausea—Conjugated Estrogens—prostate cancer	0.00232	0.00232	CcSEcCtD
Metaxalone—Hypersensitivity—Estradiol—prostate cancer	0.0023	0.0023	CcSEcCtD
Metaxalone—Pruritus—Estradiol—prostate cancer	0.00221	0.00221	CcSEcCtD
Metaxalone—Leukopenia—Docetaxel—prostate cancer	0.00221	0.00221	CcSEcCtD
Metaxalone—Somnolence—Etoposide—prostate cancer	0.00215	0.00215	CcSEcCtD
Metaxalone—Hypersensitivity—Mitoxantrone—prostate cancer	0.00214	0.00214	CcSEcCtD
Metaxalone—Leukopenia—Capecitabine—prostate cancer	0.00214	0.00214	CcSEcCtD
Metaxalone—Drowsiness—Epirubicin—prostate cancer	0.00213	0.00213	CcSEcCtD
Metaxalone—Jaundice—Epirubicin—prostate cancer	0.00207	0.00207	CcSEcCtD
Metaxalone—Dizziness—Estradiol—prostate cancer	0.00206	0.00206	CcSEcCtD
Metaxalone—Anaphylactic shock—Docetaxel—prostate cancer	0.00201	0.00201	CcSEcCtD
Metaxalone—Vomiting—Estradiol—prostate cancer	0.00199	0.00199	CcSEcCtD
Metaxalone—Rash—Estradiol—prostate cancer	0.00197	0.00197	CcSEcCtD
Metaxalone—Drowsiness—Doxorubicin—prostate cancer	0.00197	0.00197	CcSEcCtD
Metaxalone—Dermatitis—Estradiol—prostate cancer	0.00197	0.00197	CcSEcCtD
Metaxalone—Headache—Estradiol—prostate cancer	0.00196	0.00196	CcSEcCtD
Metaxalone—Jaundice—Doxorubicin—prostate cancer	0.00192	0.00192	CcSEcCtD
Metaxalone—Nausea—Estradiol—prostate cancer	0.00185	0.00185	CcSEcCtD
Metaxalone—Vomiting—Mitoxantrone—prostate cancer	0.00185	0.00185	CcSEcCtD
Metaxalone—Rash—Mitoxantrone—prostate cancer	0.00183	0.00183	CcSEcCtD
Metaxalone—Dermatitis—Mitoxantrone—prostate cancer	0.00183	0.00183	CcSEcCtD
Metaxalone—Headache—Mitoxantrone—prostate cancer	0.00182	0.00182	CcSEcCtD
Metaxalone—Somnolence—Docetaxel—prostate cancer	0.00179	0.00179	CcSEcCtD
Metaxalone—Hypersensitivity—Etoposide—prostate cancer	0.00178	0.00178	CcSEcCtD
Metaxalone—Anaphylactic shock—Prednisone—prostate cancer	0.00173	0.00173	CcSEcCtD
Metaxalone—Nausea—Mitoxantrone—prostate cancer	0.00173	0.00173	CcSEcCtD
Metaxalone—Pruritus—Etoposide—prostate cancer	0.00171	0.00171	CcSEcCtD
Metaxalone—Tension—Epirubicin—prostate cancer	0.00163	0.00163	CcSEcCtD
Metaxalone—Nervousness—Epirubicin—prostate cancer	0.00161	0.00161	CcSEcCtD
Metaxalone—Dizziness—Etoposide—prostate cancer	0.0016	0.0016	CcSEcCtD
Metaxalone—Vomiting—Etoposide—prostate cancer	0.00154	0.00154	CcSEcCtD
Metaxalone—Rash—Etoposide—prostate cancer	0.00153	0.00153	CcSEcCtD
Metaxalone—Dermatitis—Etoposide—prostate cancer	0.00152	0.00152	CcSEcCtD
Metaxalone—Headache—Etoposide—prostate cancer	0.00152	0.00152	CcSEcCtD
Metaxalone—Tension—Doxorubicin—prostate cancer	0.00151	0.00151	CcSEcCtD
Metaxalone—Nervousness—Doxorubicin—prostate cancer	0.00149	0.00149	CcSEcCtD
Metaxalone—Leukopenia—Epirubicin—prostate cancer	0.00149	0.00149	CcSEcCtD
Metaxalone—Hypersensitivity—Docetaxel—prostate cancer	0.00148	0.00148	CcSEcCtD
Metaxalone—Nausea—Etoposide—prostate cancer	0.00144	0.00144	CcSEcCtD
Metaxalone—Hypersensitivity—Capecitabine—prostate cancer	0.00143	0.00143	CcSEcCtD
Metaxalone—Pruritus—Docetaxel—prostate cancer	0.00142	0.00142	CcSEcCtD
Metaxalone—Pruritus—Capecitabine—prostate cancer	0.00138	0.00138	CcSEcCtD
Metaxalone—Leukopenia—Doxorubicin—prostate cancer	0.00138	0.00138	CcSEcCtD
Metaxalone—Anaphylactic shock—Epirubicin—prostate cancer	0.00136	0.00136	CcSEcCtD
Metaxalone—Dizziness—Docetaxel—prostate cancer	0.00133	0.00133	CcSEcCtD
Metaxalone—Dizziness—Capecitabine—prostate cancer	0.00129	0.00129	CcSEcCtD
Metaxalone—Vomiting—Docetaxel—prostate cancer	0.00128	0.00128	CcSEcCtD
Metaxalone—Hypersensitivity—Prednisone—prostate cancer	0.00128	0.00128	CcSEcCtD
Metaxalone—Rash—Docetaxel—prostate cancer	0.00127	0.00127	CcSEcCtD
Metaxalone—Dermatitis—Docetaxel—prostate cancer	0.00127	0.00127	CcSEcCtD
Metaxalone—Headache—Docetaxel—prostate cancer	0.00126	0.00126	CcSEcCtD
Metaxalone—Anaphylactic shock—Doxorubicin—prostate cancer	0.00126	0.00126	CcSEcCtD
Metaxalone—Vomiting—Capecitabine—prostate cancer	0.00124	0.00124	CcSEcCtD
Metaxalone—Rash—Capecitabine—prostate cancer	0.00123	0.00123	CcSEcCtD
Metaxalone—Pruritus—Prednisone—prostate cancer	0.00123	0.00123	CcSEcCtD
Metaxalone—Dermatitis—Capecitabine—prostate cancer	0.00123	0.00123	CcSEcCtD
Metaxalone—Headache—Capecitabine—prostate cancer	0.00122	0.00122	CcSEcCtD
Metaxalone—Somnolence—Epirubicin—prostate cancer	0.00121	0.00121	CcSEcCtD
Metaxalone—Nausea—Docetaxel—prostate cancer	0.00119	0.00119	CcSEcCtD
Metaxalone—Nausea—Capecitabine—prostate cancer	0.00116	0.00116	CcSEcCtD
Metaxalone—Dizziness—Prednisone—prostate cancer	0.00115	0.00115	CcSEcCtD
Metaxalone—Somnolence—Doxorubicin—prostate cancer	0.00112	0.00112	CcSEcCtD
Metaxalone—Vomiting—Prednisone—prostate cancer	0.0011	0.0011	CcSEcCtD
Metaxalone—Rash—Prednisone—prostate cancer	0.00109	0.00109	CcSEcCtD
Metaxalone—Dermatitis—Prednisone—prostate cancer	0.00109	0.00109	CcSEcCtD
Metaxalone—Headache—Prednisone—prostate cancer	0.00109	0.00109	CcSEcCtD
Metaxalone—Nausea—Prednisone—prostate cancer	0.00103	0.00103	CcSEcCtD
Metaxalone—Hypersensitivity—Epirubicin—prostate cancer	0.001	0.001	CcSEcCtD
Metaxalone—Pruritus—Epirubicin—prostate cancer	0.00096	0.00096	CcSEcCtD
Metaxalone—Hypersensitivity—Doxorubicin—prostate cancer	0.000925	0.000925	CcSEcCtD
Metaxalone—Dizziness—Epirubicin—prostate cancer	0.000897	0.000897	CcSEcCtD
Metaxalone—Pruritus—Doxorubicin—prostate cancer	0.000888	0.000888	CcSEcCtD
Metaxalone—Vomiting—Epirubicin—prostate cancer	0.000863	0.000863	CcSEcCtD
Metaxalone—Rash—Epirubicin—prostate cancer	0.000855	0.000855	CcSEcCtD
Metaxalone—Dermatitis—Epirubicin—prostate cancer	0.000855	0.000855	CcSEcCtD
Metaxalone—Headache—Epirubicin—prostate cancer	0.00085	0.00085	CcSEcCtD
Metaxalone—Dizziness—Doxorubicin—prostate cancer	0.00083	0.00083	CcSEcCtD
Metaxalone—Nausea—Epirubicin—prostate cancer	0.000806	0.000806	CcSEcCtD
Metaxalone—Vomiting—Doxorubicin—prostate cancer	0.000798	0.000798	CcSEcCtD
Metaxalone—Rash—Doxorubicin—prostate cancer	0.000791	0.000791	CcSEcCtD
Metaxalone—Dermatitis—Doxorubicin—prostate cancer	0.000791	0.000791	CcSEcCtD
Metaxalone—Headache—Doxorubicin—prostate cancer	0.000786	0.000786	CcSEcCtD
Metaxalone—Nausea—Doxorubicin—prostate cancer	0.000746	0.000746	CcSEcCtD
